Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease
2007-01-01 Arcaini, L; Paulli, M; Burcheri, S; Rossi, A; Spina, M; Passamonti, Francesco; Lucioni, M; Motta, T; Canzonieri, V; Montanari, M; Bonoldi, E; Gallamini, A; Uziel, L; Crugnola, M; Ramponi, A; Montanari, F; Pascutto, C; Morra, E; Lazzarino, M.
Blast phase of essential thrombocythemia: A single center study.
2009-01-01 Passamonti, Francesco; Rumi, E; Arcaini, L; Elena, C; Castagnola, C; Zappasodi, P; Bernasconi, P; Pietra, D; Pascutto, C; Cazzola, M; Lazzarino, M.
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas.
2010-01-01 Arcaini, L; Merli, M; Passamonti, Francesco; Bruno, R; Ebrusamolino, E; Sacchi, P; Rattotti, S; Orlandi, E; Rumi, E; Ferretti, V; Rizzi, S; Meli, E; Pascutto, C; Paulli, M; Lazzarino, M.
Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection
2009-01-01 Arcaini, L; Pascutto, C; Passamonti, Francesco; Bruno, R; Merli, M; Rizzi, S; Orlandi, E; Astori, C; Rattotti, S; Paulli, M; Lazzarino, M.
Myelofibrotic transformation in essentialthrombocythemia. Author reply
2009-01-01 Passamonti, Francesco; Rumi, E.; Boveri, E.; Lazzarino, M.
Immunochemotherapy with rituximab, vincristine and 5-days cyclophosphamide (R-CV) for heavily pretreated follicular lymphoma
2005-01-01 Lazzarino, M; Arcaini, L; Orlandi, E; Iacona, I; Bernasconi, P; Calatroni, S; Varettoni, M; Isa, L; Brusamolino, E; Bonfichi, M; Passamonti, Francesco; Burcheri, S; Pascutto, C; Regazzi, M.
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.
2004-01-01 Passamonti, Francesco; Rumi, E; Malabarba, L; Arcaini, L; Orlandi, E; Brusamolino, E; Pascutto, C; Cazzola, M; Lazzarino, M.
Orthogonal polynomials of equilibrium measures supported on Cantor sets
2015-01-01 Mantica, GIORGIO DOMENICO PIO
Refinable functions, functionals, and iterated function systems
2016-01-01 Calabrò, F.; Corbo Esposito, A.; Mantica, GIORGIO DOMENICO PIO; Radice, T.
Low mean impedance in 24-hour tracings and esophagitis in children: a strong connection
2016-01-01 Salvatore, Silvia; Salvatoni, Alessandro; Ummarino, D; Ghanma, A; Van der Pol, R; Rongen, A; Fuoti, M; Meneghin, F; Benninga, Ma; Vandenplas, Y.
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.
2011-01-01 Scherber, R; Dueck, Ac; Johansson, P; Barbui, T; Barosi, G; Vannucchi, Am; Passamonti, Francesco; Andreasson, B; Ferarri, Ml; Rambaldi, A; Samuelsson, J; Birgegard, G; Tefferi, A; Harrison, Cn; Radia, D; Mesa, R. A.
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
2011-01-01 Carobbio, A; Thiele, J; Passamonti, Francesco; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Gisslinger, H; Buxhofer Ausch, V; Finazzi, G; Gangat, N; Tefferi, A; Barbui, T.
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression
2011-01-01 Klampfl, T; Harutyunyan, A; Berg, T; Gisslinger, B; Schalling, M; Bagienski, K; Olcaydu, D; Passamonti, Francesco; Rumi, E; Pietra, D; Jäger, R; Pieri, L; Guglielmelli, P; Iacobucci, I; Martinelli, G; Cazzola, M; Vannucchi, Am; Gisslinger, H; Kralovics, R.
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.
2011-01-01 Elena, C; Passamonti, Francesco; Rumi, E; Malcovati, L; Arcaini, L; Boveri, E; Merli, M; Pietra, D; Pascutto, C; Lazzarino, M.
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
2011-01-01 Barbui, T; Barosi, G; Birgegard, G; Cervantes, F; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, Hc; Hehlmann, R; Hoffman, R; Kiladjian, Jj; Kröger, N; Mesa, R; Mcmullin, Mf; Pardanani, A; Passamonti, Francesco; Vannucchi, Am; Reiter, A; Silver, Rt; Verstovsek, S; Tefferi, A.
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
2011-01-01 Pardanani, A; Vannucchi, Am; Passamonti, Francesco; Cervantes, F; Barbui, T; Tefferi, A.
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis
2011-01-01 Passamonti, Francesco
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies
2011-01-01 Passamonti, Francesco; Maffioli, M; Caramazza, D; Cazzola, M.
What are RBC-transfusion-dependence and -independence?
2011-01-01 Gale, Rp; Barosi, G; Barbui, T; Cervantes, F; Dohner, K; Dupriez, B; Gupta, V; Harrison, C; Hoffman, R; Kiladjian, Jj; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Ribrag, V; Roboz, G; Saglio, G; Vannucchi, A; Verstovsek, S.
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.
2011-01-01 Elena, C; Rumi, E; Portolan, M; Della Porta, Mg; Pascutto, C; Passamonti, Francesco
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease | 1-gen-2007 | Arcaini, L; Paulli, M; Burcheri, S; Rossi, A; Spina, M; Passamonti, Francesco; Lucioni, M; Motta, T; Canzonieri, V; Montanari, M; Bonoldi, E; Gallamini, A; Uziel, L; Crugnola, M; Ramponi, A; Montanari, F; Pascutto, C; Morra, E; Lazzarino, M. | |
| Blast phase of essential thrombocythemia: A single center study. | 1-gen-2009 | Passamonti, Francesco; Rumi, E; Arcaini, L; Elena, C; Castagnola, C; Zappasodi, P; Bernasconi, P; Pietra, D; Pascutto, C; Cazzola, M; Lazzarino, M. | |
| Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. | 1-gen-2010 | Arcaini, L; Merli, M; Passamonti, Francesco; Bruno, R; Ebrusamolino, E; Sacchi, P; Rattotti, S; Orlandi, E; Rumi, E; Ferretti, V; Rizzi, S; Meli, E; Pascutto, C; Paulli, M; Lazzarino, M. | |
| Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection | 1-gen-2009 | Arcaini, L; Pascutto, C; Passamonti, Francesco; Bruno, R; Merli, M; Rizzi, S; Orlandi, E; Astori, C; Rattotti, S; Paulli, M; Lazzarino, M. | |
| Myelofibrotic transformation in essentialthrombocythemia. Author reply | 1-gen-2009 | Passamonti, Francesco; Rumi, E.; Boveri, E.; Lazzarino, M. | |
| Immunochemotherapy with rituximab, vincristine and 5-days cyclophosphamide (R-CV) for heavily pretreated follicular lymphoma | 1-gen-2005 | Lazzarino, M; Arcaini, L; Orlandi, E; Iacona, I; Bernasconi, P; Calatroni, S; Varettoni, M; Isa, L; Brusamolino, E; Bonfichi, M; Passamonti, Francesco; Burcheri, S; Pascutto, C; Regazzi, M. | |
| Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. | 1-gen-2004 | Passamonti, Francesco; Rumi, E; Malabarba, L; Arcaini, L; Orlandi, E; Brusamolino, E; Pascutto, C; Cazzola, M; Lazzarino, M. | |
| Orthogonal polynomials of equilibrium measures supported on Cantor sets | 1-gen-2015 | Mantica, GIORGIO DOMENICO PIO | |
| Refinable functions, functionals, and iterated function systems | 1-gen-2016 | Calabrò, F.; Corbo Esposito, A.; Mantica, GIORGIO DOMENICO PIO; Radice, T. | |
| Low mean impedance in 24-hour tracings and esophagitis in children: a strong connection | 1-gen-2016 | Salvatore, Silvia; Salvatoni, Alessandro; Ummarino, D; Ghanma, A; Van der Pol, R; Rongen, A; Fuoti, M; Meneghin, F; Benninga, Ma; Vandenplas, Y. | |
| The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. | 1-gen-2011 | Scherber, R; Dueck, Ac; Johansson, P; Barbui, T; Barosi, G; Vannucchi, Am; Passamonti, Francesco; Andreasson, B; Ferarri, Ml; Rambaldi, A; Samuelsson, J; Birgegard, G; Tefferi, A; Harrison, Cn; Radia, D; Mesa, R. A. | |
| Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. | 1-gen-2011 | Carobbio, A; Thiele, J; Passamonti, Francesco; Rumi, E; Ruggeri, M; Rodeghiero, F; Randi, Ml; Bertozzi, I; Vannucchi, Am; Antonioli, E; Gisslinger, H; Buxhofer Ausch, V; Finazzi, G; Gangat, N; Tefferi, A; Barbui, T. | |
| Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression | 1-gen-2011 | Klampfl, T; Harutyunyan, A; Berg, T; Gisslinger, B; Schalling, M; Bagienski, K; Olcaydu, D; Passamonti, Francesco; Rumi, E; Pietra, D; Jäger, R; Pieri, L; Guglielmelli, P; Iacobucci, I; Martinelli, G; Cazzola, M; Vannucchi, Am; Gisslinger, H; Kralovics, R. | |
| Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. | 1-gen-2011 | Elena, C; Passamonti, Francesco; Rumi, E; Malcovati, L; Arcaini, L; Boveri, E; Merli, M; Pietra, D; Pascutto, C; Lazzarino, M. | |
| European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | 1-gen-2011 | Barbui, T; Barosi, G; Birgegard, G; Cervantes, F; Finazzi, G; Griesshammer, M; Harrison, C; Hasselbalch, Hc; Hehlmann, R; Hoffman, R; Kiladjian, Jj; Kröger, N; Mesa, R; Mcmullin, Mf; Pardanani, A; Passamonti, Francesco; Vannucchi, Am; Reiter, A; Silver, Rt; Verstovsek, S; Tefferi, A. | |
| JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. | 1-gen-2011 | Pardanani, A; Vannucchi, Am; Passamonti, Francesco; Cervantes, F; Barbui, T; Tefferi, A. | |
| Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis | 1-gen-2011 | Passamonti, Francesco | |
| Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies | 1-gen-2011 | Passamonti, Francesco; Maffioli, M; Caramazza, D; Cazzola, M. | |
| What are RBC-transfusion-dependence and -independence? | 1-gen-2011 | Gale, Rp; Barosi, G; Barbui, T; Cervantes, F; Dohner, K; Dupriez, B; Gupta, V; Harrison, C; Hoffman, R; Kiladjian, Jj; Mesa, R; Mc Mullin, Mf; Passamonti, Francesco; Ribrag, V; Roboz, G; Saglio, G; Vannucchi, A; Verstovsek, S. | |
| Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. | 1-gen-2011 | Elena, C; Rumi, E; Portolan, M; Della Porta, Mg; Pascutto, C; Passamonti, Francesco |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- Articoli su Riviste35263
Data di pubblicazione
- In corso di stampa26
- 2020 - 202710432
- 2010 - 201911845
- 2000 - 20097910
- 1990 - 19993628
- 1980 - 19891162
- 1970 - 1979252
- 1967 - 19698
Editore
- Edizioni Luigi Pozzi Srl:via Pana...51
- Japadre Editore, L'Aquila36
- WILEY34
- Elsevier BV:PO Box 211, 1000 AE A...31
- ELSEVIER SCIENCE BV29
- Franco Angeli Riviste SRL:viale M...28
- Springer Verlag Germany:Tiergarte...28
- -Roma: [s.n.]. -Artegierre-Esseze...26
- Elsevier B.V.23
- Royal Society of Chemistry:Thomas...21
Rivista
- PHYSICAL REVIEW LETTERS216
- LA RADIOLOGIA MEDICA180
- NUCLEAR INSTRUMENTS & METHODS IN ...176
- ASTRONOMY & ASTROPHYSICS168
- MONTHLY NOTICES OF THE ROYAL ASTR...165
- PLOS ONE163
- PHYSICS LETTERS. SECTION B154
- SCIENTIFIC REPORTS153
- THROMBOSIS AND HAEMOSTASIS145
- IL PROTAGORA140
Serie
- PROCEEDINGS OF INTERNATIONAL MATH...1
Keyword
- Humans1627
- Female817
- Male695
- Middle Aged526
- COVID-19518
- Aged481
- Adult464
- Italy345
- SARS-CoV-2317
- Treatment Outcome240
Lingua
- eng18885
- ita2906
- fre60
- spa55
- ger35
- por14
- bul9
- rus8
- gre6
- chi3
Accesso al fulltext
- no fulltext24730
- reserved5245
- open5085
- restricted107
- partially open93
- mixed2
- embargoed1